Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

531 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Hassan R, et al. Among authors: reck m. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. doi: 10.1158/1078-0432.CCR-14-0804. Epub 2014 Sep 17. Clin Cancer Res. 2014. PMID: 25231400 Free PMC article. Clinical Trial.
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Manegold C, et al. Among authors: reck m. Ann Oncol. 2005 Jun;16(6):923-7. doi: 10.1093/annonc/mdi187. Epub 2005 Apr 11. Ann Oncol. 2005. PMID: 15824080 Free article. Clinical Trial.
Pemetrexed-cisplatin combination in mesothelioma.
Reck M, Gatzemeier U. Reck M, et al. Expert Rev Anticancer Ther. 2005 Apr;5(2):231-7. doi: 10.1586/14737140.5.2.231. Expert Rev Anticancer Ther. 2005. PMID: 15877521 Review.
A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer.
Talbot DC, von Pawel J, Cattell E, Yule SM, Johnston C, Zandvliet AS, Huitema AD, Norbury CJ, Ellis P, Bosquee L, Reck M. Talbot DC, et al. Among authors: reck m. Clin Cancer Res. 2007 Mar 15;13(6):1816-22. doi: 10.1158/1078-0432.CCR-06-0249. Clin Cancer Res. 2007. PMID: 17363538 Free article. Clinical Trial.
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.
Gridelli C, Kaukel E, Gregorc V, Migliorino MR, Müller TR, Manegold C, Favaretto A, Martoni A, Caffo O, Schmittel A, Rossi A, Russo F, Peterson P, Muñoz M, Reck M. Gridelli C, et al. Among authors: reck m. J Thorac Oncol. 2007 Mar;2(3):221-9. doi: 10.1097/JTO.0b013e318031cd62. J Thorac Oncol. 2007. PMID: 17410045 Free article. Clinical Trial.
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
Felip E, Rojo F, Reck M, Heller A, Klughammer B, Sala G, Cedres S, Peralta S, Maacke H, Foernzler D, Parera M, Möcks J, Saura C, Gatzemeier U, Baselga J. Felip E, et al. Among authors: reck m. Clin Cancer Res. 2008 Jun 15;14(12):3867-74. doi: 10.1158/1078-0432.CCR-07-5186. Clin Cancer Res. 2008. PMID: 18559607 Clinical Trial.
531 results